Suspects in the tale of lupus‐associated thrombocytopenia

Summary Immunologically mediated thrombocytopenia is a frequent clinical manifestation in patients with systemic lupus erythematosus (SLE). Autoantibodies targeting platelet membrane glucoproteins have a central role in peripheral platelet destruction. Autoantibodies against thrombopoietin are also present in about one‐third of patients, but their pathogenetic role is obscure. Thirty‐eight serum samples from SLE patients were tested for anti‐platelet antibodies, anti‐thrombopoietin antibodies and levels of circulating thrombopoietin. Bone marrow histology was also assessed. Thirty‐nine per cent of sera displayed anti‐thrombopoietin antibodies and 29% had circulating anti‐platelet antibodies. Anti‐thrombopoietin antibodies were associated with lower thrombopoietin concentrations, and lower mean platelet values in long‐term follow‐up. Anti‐platelet antibodies were present in about 40% of thrombocytopenic and non‐thrombocytopenic individuals but were absent in patients who had recovered from thrombocytopenia, supporting their pathogenetic role. Both autoantibodies were absent in control sera from patients with rheumatoid arthritis and primary Sjögren’s syndrome. Decreased bone marrow cellularity, normal or low number of hypolobulated, pyknotic megakaryocytes and stromal alterations were prominent findings in thrombocytopenic SLE patients, suggesting a defect in megakaryopoiesis. These findings were not evident in specimens from patients with idiopathic thrombocytopenic purpura who had increased megakaryocytes, normal cellularity and absence of stromal alterations. In conclusion, peripheral destruction due to platelet autoantibodies, anti‐thrombopoetin antibodies, lower effective circulating thrombopoetin and impaired compensatory response due to bone marrow damage interact in SLE and thrombocytopenia ensues.